Clinical uroselectivity: Evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstruction

British Journal of Urology

Volumn 79, Issue 6, 1997, Pages 898-906

  Buzelin, J M ^a   Delauche Cavallier, M C ^a   Roth, S ^a   Geffriaud Ricouard, C ^a   Santoni, J P ^a  

^a HÔTEL DIEU   (France)

Author keywords

Benign prostatic obstruction; Clinical uroselectivity; Orthostatic hypotension; Safety profile; Slow release alfuzosin; 1 blocker therapy

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; ASTHENIA; BLADDER NECK STENOSIS; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; EDEMA; FATIGUE; HEADACHE; HEART INFARCTION; HEART PALPITATION; HUMAN; HYPERTENSION; IMPOTENCE; MAJOR CLINICAL STUDY; MALAISE; MALE; META ANALYSIS; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SLOW RELEASE FORMULATION; SUPINE POSITION; SYMPTOM; SYNCOPE; URINE FLOW RATE; VASODILATATION; VERTIGO;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; HUMANS; HYPERTENSION; MALE; PROSTATIC HYPERPLASIA; QUINAZOLINES; TREATMENT OUTCOME; URINARY RETENTION; URINATION;

EID: 0031400346     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.1997.00131.x     Document Type: Article

References (26)

1. Eri LM, Tveter KJ. Alpha blockade in the treatment of symptomatic benign prostatic hyperplasia. J Urol 1995; 154: 923-34
2. Jardin A, Bensadoun H, Delauche-Cavallier MC, Attali P and the BPH-ALF Group. Alfuzosin for treatment of benign prostatic hypertrophy, lancet 1991; 337: 1457-61
3. Jardin A, Bensadoun H, Delauche-Cavallier MC, Attali P and the BPH-ALF Group. Long term treatment of benign prostatic hypertrophy with alfuzosin: a 12-18 month assessment. Er J Urol 1993; 72: 615-20
4. Jardin A, Bensadoun H. Delauche-Cavallier MC, Attali P and the BPH-ALF Group. Long term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 month survey. Br J Urol 1994; 74: 579-84
5. 1, blocker, in patients with benign prostatic hypertrophy. Br J Urol 1992; 70: 58-64
6. Buzelin JM, Hebert M, Blondin P and the Prazalf Group. Alpha blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. Br J Urol 1993; 72: 922-7
7. Stephenson TP, Jensen RD and the Pranalf Group. A placebo-controlled study of the efficacy and tolerability of alfuzosin and prazosin for the treatment of benign prostatic hypertrophy (BPH). Proceedings XIth Congress of the European Association of Urology, Berlin Germany, 1994; 25: abstr 48
8. 1, adrenergic blocker alfuzosin. Eur Urol 1993; 24 (suppl 1): 34-47
9. Lukacs B, Blondin P, McCarthy C, Du Boys B, Grippon P, Lassale C. Safety profile of 3 months therapy with alfuzosin in 13 339 patients suffering from benign prostatic hypertrophy. Eur Urol 1996; 29: 29-35
10. Greenberg RN. Overview of patients compliance with medication dosing: a literature review. Clin Therap 1984; 6: 592-99
11. 1 receptor antagonist. Yakugaku Zasshi 1996; 115: 773-789
12. Delmas V, Coulange C, Caille P, Delauche-Cavallier MC, Geffriaud C, Proffit O. A placebo-controlled study of sustained release alfuzosin in benign prostatic hyperplasia. Proceedings XIth Congress of the European Association of Urology. Berlin Germany, 1996; 25: Abstr 67
13. Buzelin JM, Roth S, Geffriaud-Ricouard C, Delauche-Cavallier MC, and the ALGEBI Study Group. Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia (BPH). Eur Urol 1997; 31: 190-8.
14. Lipstiz LA. Orthostatic hypotension in the elderly. New Engl J Med 1989; 321: 952-56
15. Andersson KE. Alpha blocker therapy in benign prostatic hyperplasia 3. Uroselectivity, In Cockett AT, ed., Proceedings of the 3rd International Consultation on Benign Prostatic Hyperplasia. C Monaco, June 1995: 538-48
16. Ford AP, Arredondo NF, Blue DR et al. (N(2-(2-cyclopropylmethoxyphenoxy) ethyl)-5-chloro-alpha, alpha-dimethyl-1H-indole-3 ethamine hydrochloride) a selective alpha 1A-adrenoceptor antagonist, displays low affinity for functional alpha 1-adrenoceptors in human prostate: implications for adrenoceptor classification. Mol Pharmacol 1996; 49: 209-15
17. Testa R, Guarneri L, Taddei C et al. Functional antagonistic activity of Rec 15/2739, a novel alpha-1 antagonist selective for the lower urinary tract, on noradrenaline-induced contraction of human prostate and mesenteric artery. J Pharmacol Exp Ther 1996; 277: 1237-46
18. Myers MC, Kearns PM, Kennedy DS, Fischer RH. Postural hypotension and diuretic therapy in the elderly. Can Med Assoc J 1974; 119: 581-6
19. 1-adrenoceptor antagonist in the lower urinary tract. Br J Pharmacol 1993; 109: 1282-9
20. Martin D, Jammes D, Angel I. Effects of alfuzosin on urethral and blood pressures in conscious male rats. Life Sci 1995; 57: 387-91
21. 1 adrenoceptor antagonists differentially control serotonin release in the hippocampus and striatum: a microdialysis study. Eur J Pharmacol 1994; 261: 59-64
22. Perrigot M, Delauche-Cavallier MC, Amarenco G, Geffriaud C, Stalla-Bourdillon A, Costa P and the DORALI study group. Effect of intravenous alfuzosin on urethral pressure in patients with neurogenic bladder disease. Neurourol Urodynam 1996; 15: 119-31
23. Lepor H. Non operative management of benign prostatic hypertrophy. J Urol 1989; 141: 1283-9
24. Löwe FC. Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis. Urology 1994; 44: 46-51
25. 1 blocker doxazosin in the treatment of benign prostatic hyperplasia. Eur Urol 1993; 24: 319-26
26. 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostastic obstruction (symptomatic BPH). Br J Urol 1995; 76: 325-36